Novogene Europe has enhanced its single-cell RNA sequencing capabilities at the Cambridge Omics Centre, providing advanced sequencing services to researchers in the UK.
This development leverages Novogene's established expertise in single-cell technologies, integrating specialized project support, sequencing infrastructure, and bioinformatics analysis. The aim is to facilitate deeper biological insights from complex samples, responding to the increasing demand for accessible single-cell transcriptomics.
The single-cell sequencing service allows researchers to analyze gene expression at the single-cell or single-nucleus level, enabling the exploration of cellular diversity and the identification of rare cell populations. This capability is crucial for understanding how various cell types contribute to biological functions.
This initiative follows the recent introduction of Novogene’s Untargeted Metabolomics Service and is part of a broader strategy to enhance the capabilities at the Cambridge site. The service focuses on 3′ gene expression using advanced technology, including GEM-X chemistry and high-throughput Illumina sequencing, catering to various research fields such as oncology, immunology, and drug discovery.
As Tingting Zhou, VP of Novogene Europe, highlighted, the expansion of single-cell sequencing services is pivotal for researchers aiming to dissect complex biological systems, thus reinforcing the Cambridge Omics Centre's role as a vital hub for multiomics research in the UK.